NextGenNK is a Competence Center founded by Sweden’s Innovation Agency. It was launched in January 2020, for the development of next generation NK cell-based cancer immunotherapies. The Center is coordinated by Karolinska Institutet and collaborates with the Karolinska University Hospital and prominent national and international industrial partners. XNK Therapeutics is one of the founding partners of the Competence Center. The collaboration will extend for a period of five years.